Trends for Pharma ETFs

 

See also ETF lists for: Pharma, Equity, Health care

Strongest Trends Summary For Motif Pharma

Pharma ETFs on average are in the long-term up 216% in 13 years.

 

See how to gain 20% in 14 sec with TrendsInvesting

 

You can switch the trend horizon using links provided in the summary above. For more information about relative trends methodology see relative trends.

Share on StockTwits

Pharma, Equity, Health care ETFs
IHE

[IHE] iShares Dow Jones US Pharm Indx

The investment seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the "underlying index"), which measures the performance of the pharmaceuticals sector of the U.S. equity market. The fund is non-diversified.

PJP

[PJP] PowerShares Dynamic Pharmaceuticals

The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceuticals IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. It is non-diversified.

PPH

[PPH] Market Vectors Pharmaceutical ETF

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Pharmaceutical 25 Index (the "Pharmaceutical Index"). The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

XPH

[XPH] SPDR S&P Pharmaceuticals

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Strongest Trends Summary Related To Pharma

Equity

Health care

Pharma ETFs on average are in the long-term up 216% in 13 years.
Pharma, U.S. ETFs on average are in the long-term up 216% in 13 years.

 

News

2017-10-17 10:26:41

Neothetics's stock rockets on heavy volume after merger deal

2017-10-16 12:33:33

President Trump reiterates that drug companies 'getting away with murder' but says not much else

2017-10-16 12:33:33

President Trump reiterates that drug companies 'getting away with murder' but says not much else

2017-10-02 12:35:00

CORRECTING and REPLACING Announcing VanEck Vectors Equity ETF’s September 2017 Distributions

2017-09-29 17:25:00

Announcing VanEck Vectors Equity ETF’s September 2017 Distributions

2017-09-26 13:55:16

The dollar will strengthen as the US is the only game in town: NYSE trader

2017-09-26 13:55:16

Any stock weakness is end-of-quarter related: NYSE trader

2017-09-22 13:14:09

Dow 23,000 hinges on earnings season: NYSE trader

2017-09-22 09:40:00

Yahoo Finance Live: Midday Movers - Sep 22nd, 2017

2017-09-19 17:09:00

ETF Flopper: Repeal and Replace Revived, Sinks Health-Care Stocks

2017-09-19 10:38:11

An Update on Novartis’s Sandostatin, Afinitor, and Exjade

2017-09-14 07:39:36

TEVA Depends on This for Revenue Growth

2017-09-12 07:37:03

How Merck’s Diabetes Portfolio Performed in 2Q17

2017-09-11 10:36:52

How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17

2017-09-11 09:06:51

Behind the Latest Developments for Merck’s Keytruda

2017-09-11 07:36:59

Introducing Merck’s 2Q17 Immuno-Oncology Blockbuster

2017-09-11 07:36:36

Where Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17

2017-09-08 09:07:17

This Could Drive Jazz Pharmaceuticals’ Revenue Growth

2017-09-08 07:37:38

Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018

2017-09-06 09:06:28

Performance of AstraZeneca’s Other Products in 2Q17

2017-09-05 09:06:30

Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings

2017-09-05 07:37:18

Performance of AstraZeneca’s Growth Platforms in 2Q17

2017-09-04 10:36:44

Eli Lilly’s Cardiovascular Products in 2Q17

2017-09-04 09:06:46

Performance of Eli Lilly’s Neuroscience Products in 2Q17

2017-09-01 10:37:34

Performance of Eli Lilly’s Endocrine Franchise in 2Q17

2017-09-01 10:36:14

How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17

2017-09-01 09:06:18

Pfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17

2017-09-01 07:36:41

Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

2017-09-01 07:36:25

A Post-2Q17 Look at Pfizer’s Internal Medicines

2017-08-31 15:02:29

Eli Lilly’s Valuations after Its 2Q17 Earnings

2017-08-31 13:39:08

Why $475,000 isn't actually that expensive for Novartis's new drug

2017-08-31 13:39:08

Why $475,000 isn't actually that expensive for Novartis's new drug

2017-08-31 13:05:00

Why a $475,000 drug price tag isn't expensive

2017-08-31 13:05:00

Why a $475,000 drug price tag isn't expensive

2017-08-31 12:34:10

Changes in GlaxoSmithKline’s Valuation after 2Q17

2017-08-31 07:38:22

How Novartis’s Sandoz Performed in 2Q17

2017-08-31 07:36:56

Bristol-Myers Squibb’s Immunoscience Products in 2Q17

2017-08-30 14:27:53

Trump can lower U.S. drug prices by fixing NAFTA

2017-08-30 14:27:53

Trump can lower U.S. drug prices by fixing NAFTA

2017-08-30 10:37:00

Performance of Bristol-Myers Squibb’s Eliquis in 2Q17

2017-08-30 07:36:21

Johnson & Johnson’s Medical Devices Segment in 2Q17

2017-08-29 07:40:39

Johnson & Johnson’s 2Q17 Performance, by Segment

2017-08-28 10:36:16

How Merck’s Zepatier and Isentress Are Positioned after 2Q17

2017-08-28 09:06:23

A Look into Merck’s Immunology and Oncology Portfolio

2017-08-23 13:30:50

I'm still bullish—Trump was just throwing red meat to his base: NYSE trader

2017-08-23 11:54:10

What Jazz Pharmaceuticals Expects for Vyxeos

2017-08-23 11:53:47

JAZZ Is Focused on Increasing Market Adoption of Defitelio

2017-08-23 09:53:34

Jazz Pharmaceuticals Is Focused on Label Expansion of Defitelio

2017-08-23 09:08:01

Defitelio Continues to Demonstrate Robust Demand Trends in 2017

2017-08-22 10:36:43

The Future of JAZZ’s Low-Sodium Investigational Drugs

2017-08-22 09:07:36

How Allergan’s US Specialized Therapeutics Segment Performed in 2Q17

2017-08-22 07:37:28

Behind Xyrem’s Solid Demand Trends in 2017

2017-08-22 07:36:25

Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

2017-08-21 16:05:52

Inside Jazz’s Net Profit Margin Expectations for 2017

2017-08-21 14:36:12

Why Jazz Is Expected to Report a Robust Revenue Growth Rate

2017-08-18 14:37:47

Stock pickers and hedge funds will always be around: NYSE trader

2017-08-18 14:37:47

Stocks set to rally once the current craziness is corralled: NYSE trader

2017-08-17 07:37:32

Sanofi’s Revenue Growth in 2Q17

2017-08-17 07:36:17

How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

2017-08-15 09:06:11

Pfizer’s Important Product Developments in 2Q17

2017-08-14 14:52:40

Why investors should ignore the news cycle: trader

2017-08-14 12:01:00

Merck: Trump Tweets…And No One Cares?

2017-08-14 10:25:16

Why Vertex Pharmaceuticals Incorporated VRTX Stock Isn’t Worth the Risk

2017-08-11 17:35:43

Pfizer’s 2Q17 Earnings: What You Need to Know

2017-08-11 08:42:57

Peregrine Pharmaceuticals laid off one-fifth of its workforce

2017-08-10 10:36:47

Celgene’s Abraxane Continued Steady Growth in 2Q17

2017-08-09 11:34:25

Stocks down, gold and bonds surge as North Korea tensions escalate

2017-08-08 11:37:19

Dow on track for Day 10 of record-setting gains

2017-08-07 13:30:32

Why the financial media is too bearish on stocks: CME trader

2017-08-07 12:10:35

Teva's stock keeps plunging on heavy volume after Morgan Stanley downgrade

2017-08-07 11:24:53

Stocks struggle as Dow record winning streak on the line

2017-08-07 09:53:37

How Valeant Pharmaceuticals Intl Inc VRX Stock Can Make a Comeback

2017-08-07 09:45:01

Q2 Earnings Fail to Impress Pharma ETF

2017-08-07 09:45:01

Q2 Earnings Fail to Impress Pharma ETF

2017-08-07 09:45:01

Q2 Earnings Fail to Impress Pharma ETF

2017-08-04 14:11:29

Stocks should tack on more summer gains after today's jobs report: trader

2017-08-04 13:57:00

Valeant Pharmaceuticals Intl Inc VRX Stock: Stupid Is as Stupid Does

2017-08-03 11:34:27

Stocks drop as investors mull weak economic data

2017-08-03 09:59:00

Three Large Cap Pharma Picks That Can Outperform This Year

2017-08-03 07:55:26

Teva's stock plunges on heavy volume after profit miss and slashed outlook

2017-08-01 11:21:17

Buy Teva Pharmaceutical Industries Ltd ADR TEVA Stock Before Q2 Earnings

2017-08-01 10:41:15

How Gilead Sciences’ HCV Franchise Is Positioned after 2Q17

2017-08-01 09:09:56

Dupixent Could Substantially Drive Regeneron’s Growth

2017-08-01 07:41:47

GlaxoSmithKline’s 2Q17 Earnings: Business Segments

2017-08-01 07:41:10

Bristol-Myers Squibb’s 2Q17 Earnings: Virology Products

2017-07-31 18:05:43

Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo

2017-07-31 16:36:04

Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17

2017-07-31 16:24:06

Inside Pfizer’s 2Q17 Earnings: Analyst Estimates

2017-07-31 14:38:10

Bristol-Myers Squibb Reports Growth in 2Q17

2017-07-31 07:40:34

Eli Lilly in 2Q17: Humulin and Endocrine Products

2017-07-28 17:05:52

Eli Lilly in 2Q17: Performance of New Products

2017-07-28 15:36:48

Eli Lilly’s Business Segments in 2Q17

2017-07-28 14:34:44

What Trump could do to make Obamacare ‘implode’

2017-07-28 14:00:43

Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year

2017-07-28 09:42:00

Oh, Snap! Obamacare Lives, Now What?

2017-07-28 07:36:15

Behind Pfizer’s Legacy Established Products Performance in 2017

2017-07-27 11:25:40

Stocks surge to new highs as Facebook lifts Nasdaq

2017-07-27 10:35:51

How Pfizer’s Internal Medicines Is Positioned in 2017

2017-07-27 07:44:14

Analysts’ Recommendations for AstraZeneca in 2Q17

2017-07-26 16:35:43

Bristol-Myers Squibb’s 2Q17 Estimates: Expect Growth!

2017-07-26 14:38:53

Bristol-Myers Squibb’s 2Q17 Earnings: Analysts’ Estimates

2017-07-25 16:25:42

Inside GlaxoSmithKline’s 2Q17 Earnings Estimates

2017-07-24 13:05:51

Foreign Exchange Impacts Novartis’s Growth in 2Q17

2017-07-24 12:35:43

What Analysts Recommend for Eli Lilly ahead of 2Q17 Results

2017-07-24 10:37:38

Johnson & Johnson: Consumer Products in 2Q17

2017-07-24 10:35:44

How Merck’s Animal Health Business Is Expected to Perform in 2017

2017-07-24 09:40:00

Yahoo Finance Live: Midday Movers - Jul 24th, 2017

2017-07-24 09:13:43

What Analysts Predict for Eli Lilly’s 2Q17 Earnings

2017-07-24 07:38:21

Johnson & Johnson: Pharmaceuticals in 2Q17

2017-07-20 09:40:00

Yahoo Finance Live: Midday Movers - Jul 20th, 2017

2017-07-19 11:55:03

J&J Brightens Outlook: Healthcare ETFs in Focus

2017-07-18 12:32:06

US dollar weakness is the one victory for Trump after health care failure: NYSE trader

2017-07-18 12:32:06

Expect a great week for tech earnings except IBM: NYSE trader

2017-07-18 12:32:06

Not owning stocks in this market is crazy: NYSE trader

2017-07-18 11:40:01

Big banks weigh on stocks as US dollar weakens

2017-07-18 09:24:00

Ding Dong, the GOP Health Care Bill is Dead

2017-07-17 10:39:32

Analysts’ Latest Recommendations for Johnson & Johnson

2017-07-17 10:27:26

Novartis’s 2Q17 Earnings: Analyst Estimates

2017-07-17 07:38:19

Johnson & Johnson’s 2Q17 Estimates: Consumer Healthcare

2017-07-14 14:10:00

Drugged: Federal Reserve concerned about the opioid epidemic

2017-07-14 11:35:17

Financials weigh on stocks after mixed economic and earnings news

2017-07-14 10:37:44

Behind Allergan’s Business Segments and Revenues

2017-07-14 09:09:13

Understanding Allergan’s Revenue Stream for 2017

2017-07-14 07:40:11

What Allergan’s Valuation as of July 13 Tells Us

2017-07-11 13:34:00

Sorry Trump—Obamacare is alive and well

2017-07-11 10:47:02

This week could be make or break for the GOP health care bill

2017-07-11 09:07:33

Farxiga Could See Robust Demand in International Markets in 2017

2017-07-10 15:10:07

What Lies Ahead for Pharma ETFs in Second Half 2017

2017-07-10 15:10:07

What Lies Ahead for Pharma ETFs in Second Half 2017

2017-07-10 15:10:07

What Lies Ahead for Pharma ETFs in Second Half 2017

2017-07-10 15:10:07

What Lies Ahead for Pharma ETFs in Second Half 2017

2017-07-10 12:45:59

Performance of Zoetis Stock in 2Q17

2017-07-10 11:36:00

Stocks mixed but tech strength mounts

2017-07-10 10:37:23

How Bristol-Myers Squibb Stock Has Performed in 2Q17

2017-07-10 07:39:13

What We Can Expect from Eli Lilly and Company in 2Q17

2017-07-10 07:21:56

Kala sets terms of IPO to raise up to $96 million

2017-07-07 16:07:25

A Look at Pharmaceutical ETFs in 2Q17

2017-07-07 12:00:00

Improving Health for This Pharma ETF

2017-07-06 07:45:09

Egalet's stock plunges toward record low after stock offering plan

2017-07-05 09:06:36

Johnson & Johnson’s Consumer Business in 1Q17

2017-07-04 10:37:45

Johnson & Johnson’s Pharmaceuticals Business in 1Q17

2017-07-04 09:06:36

Performance of Merck’s Gardasil and Other Human Vaccines in 1Q17

2017-07-04 07:38:58

Johnson & Johnson’s Revenues in 1Q17

2017-07-04 07:36:36

Keytruda’s Developments in June 2017

2017-07-03 12:25:39

Gordon Gekko was right: Stocks are now a zero-sum game

2017-07-03 12:25:39

Gordon Gekko was right: Stocks are now a zero-sum game

2017-07-03 10:37:24

How Did Keytruda Perform in 1Q17?

2017-07-03 09:10:19

AstraZeneca May Witness a Fall in 2017 Net Profit Margin

2017-06-30 17:27:00

Announcing VanEck Vectors Equity ETF’s June 2017 Distributions

2017-06-30 13:44:42

Why the US is losing the war on drug prices: trader

2017-06-30 13:44:42

Why the US is losing the war on drug prices: trader

2017-06-30 11:37:29

Stocks edge up as Q2 draws to a close

2017-06-30 11:37:29

Stocks edge up as Q2 draws to a close

2017-06-30 07:38:24

Merck’s Anacetrapib and REVEAL Study

2017-06-29 08:00:00

Trending: OPEC Fails to Scare Oil Short-Sellers

2017-06-28 10:36:01

Pfizer’s Profitability in 1Q17

2017-06-27 10:36:38

A Look at Pfizer’s Revenue for 1Q17

2017-06-26 08:40:31

Pfizer’s Progress on Its Group B Streptococcus Vaccine

2017-06-23 13:36:14

Why investors flipped 180 on health care stocks today: NYSE trader

2017-06-23 13:36:14

Why investors flipped 180 on health care stocks today: NYSE trader

2017-06-23 12:13:22

Medical groups diagnose GOP health care bill: It’s not well

2017-06-22 11:38:26

Does Valeant Pharmaceuticals Intl Inc VRX Stock Have a Bull Case?

2017-06-21 15:07:48

Why did these generic drugs’ prices jump as much as 85%?

2017-06-21 13:03:09

Drug stocks surge on report that President Trump plans to ease industry regulations

2017-06-21 11:43:10

Why one Wall Street strategist is cautious on techs and financials

2017-06-21 09:08:03

Analyzing Bristol-Myers Squibb’s Valuation on June 20

2017-06-20 12:09:22

SK Biotek to Acquire Manufacturing Facility in Swords, Ireland

2017-06-20 07:36:03

Key Updates on Eli Lilly’s Jardiance

2017-06-19 09:07:30

FDA Approves Eli Lilly’s Humalog Junior KwikPen

2017-06-19 07:45:53

Valeant's stock surges after largest shareholder John Paulson elected to board

2017-06-08 10:36:19

Why Pfizer’s Products Lost Market Share in 1Q17

2017-06-08 09:06:56

What Drove Pfizer in 1Q17?

2017-06-07 14:22:31

What Happened to Pfizer’s Valuation after 1Q17?

2017-06-02 09:07:11

Performance of Eli Lilly’s Oncology Products in 1Q17

2017-06-02 07:37:10

Performance of Eli Lilly’s New Products Portfolio in 1Q17

2017-06-02 07:36:50

Inside Novartis’s Generics Business Now

2017-06-01 10:37:37

GlaxoSmithKline’s Consumer Healthcare Segment in 1Q17

2017-05-30 15:35:55

Changes in Johnson & Johnson’s Revenue in 1Q17

2017-05-30 14:02:29

How Johnson & Johnson’s Valuation Changed Post-1Q17

2017-05-25 07:35:53

Merck’s Immunology and Cardiovascular Franchise in 1Q17

2017-05-24 10:36:50

Performance of Merck’s Diabetes Portfolio in 1Q17

2017-05-24 09:06:37

Gardasil and Merck’s Vaccines Business in 1Q17

2017-05-19 07:36:57

What Happened to Bristol-Myers Squibb’s Opdivo in 1Q17?

2017-05-18 09:07:43

Behind Bristol-Myers Squibb’s 1Q17 Performance

2017-05-18 07:37:47

Inside Bristol-Myers Squibb’s Valuation after the 1Q17 Earnings

2017-05-17 17:37:09

The Latest Market Trends Every Biopharma Investor Needs to Know

2017-05-11 10:36:45

Understanding Allergan’s Valuation after the 1Q17 Results

2017-05-10 18:05:46

Behind Allergan’s US Specialized Therapeutics Segment in 1Q17

2017-05-09 09:06:19

Comparing Pfizer’s Valuation to Peers after 1Q17 Earnings

2017-05-09 07:35:57

Pfizer’s Corporate and Pipeline Developments in 1Q17

2017-05-09 07:14:52

Valeant's stock soars after profit beats expectations

2017-05-08 17:42:00

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain

2017-05-08 09:06:28

Pfizer: Why Revenues Fell in 1Q17 for Some Products

2017-05-08 09:01:29

Mallinckrodt's stock jumps after profit and sales beat

2017-05-05 14:17:07

Analyzing Pfizer’s 1Q17 Earnings

2017-05-03 14:58:06

Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

2017-05-02 10:36:57

How GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17

2017-05-02 07:38:07

Analyzing GlaxoSmithKline’s Global Pharmaceutical Performance

2017-05-02 07:37:34

Eli Lilly’s 1Q17 Earnings: Cialis and Other Cardiovascular Products

2017-05-01 13:21:19

Pfizer’s 1Q17 Earnings: Analysts’ Estimates

2017-05-01 07:39:46

Eli Lilly’s 1Q17 Earnings: Humalog and Other Endocrine Products

2017-04-28 15:35:48

Eli Lilly’s Business Segments and Their Performance in 1Q17

2017-04-28 09:08:00

1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business

2017-04-27 09:08:21

Dupixent Expected to Be a Solid Addition to Regeneron’s Portfolio

2017-04-27 07:36:57

Analysts’ Ratings and Recommendations for Bristol-Myers Squibb

2017-04-26 12:05:43

What Analysts Recommend for AstraZeneca

2017-04-26 10:37:52

A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

2017-04-26 09:09:06

Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment

2017-04-26 07:37:24

A Look at Bristol-Myers Squibb’s Oncology Segment in 1Q17

2017-04-24 14:20:04

Why some investors aren't thrilled about Becton Dickinson buying C.R. Bard

2017-04-24 14:20:04

Why medical device stocks may rise if Obamacare is repealed

2017-04-24 11:37:39

Stocks soar after French elections ahead of busiest earnings week in 10 years

2017-04-24 09:07:50

Novartis’s 1Q17 Estimates for Alcon

2017-04-21 15:05:48

Analysts Expect Novartis’s Revenues to Remain Flat in 1Q17

2017-04-21 10:36:30

Eli Lilly’s Estimate for Strattera, Other Neuroscience Products

2017-04-21 09:06:41

Johnson & Johnson’s Consumer Segment’s 1Q17 Earnings

2017-04-21 09:06:31

How Will Eli Lilly’s Alimta and Other Oncology Products Perform?

2017-04-21 07:36:59

Johnson & Johnson’s Pharmaceuticals Segment’s 1Q17 Earnings

2017-04-20 17:05:44

Johnson & Johnson’s 1Q17 Segment-by-Segment Performance

2017-04-20 11:31:53

Analyst Estimates for Eli Lilly’s 1Q17 Earnings

2017-04-19 10:55:02

Lackluster J&J Q1 Pushes Healthcare ETFs Down

2017-04-17 12:17:00

5 ETFs to Buy If You Love Johnson & Johnson's First-Quarter Earnings

2017-04-14 10:36:44

Analysts’ Ratings for Johnson & Johnson in 1Q17

2017-04-14 07:37:15

Analyzing Johnson & Johnson’s Medical Devices Segment

2017-04-13 16:35:44

Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment

2017-04-11 13:05:49

The Larger Aims of Obamacare: An Overview

2017-04-11 11:29:44

The Hybrid US Healthcare System: An Overview

2017-04-11 11:29:44

The Hybrid US Healthcare System: An Overview

2017-04-11 07:36:28

Analyzing the Performance of Abbott Laboratories in 1Q17

2017-04-10 07:36:42

How Pfizer Stock Performed in 1Q17

2017-04-07 18:59:00

ETF Flyers: Pharmaceuticals

2017-04-07 18:59:00

ETF Flyers: Pharmaceuticals

2017-04-07 15:05:56

Performance of Merck & Co. Stock in 1Q17

2017-04-05 08:32:09

There Is Value To Be Had With The Right Healthcare ETFs

2017-04-04 12:24:00

There's Value in Healthcare ETFs

2017-04-04 10:36:41

These Key Product Developments Could Help Pfizer

2017-04-04 09:06:40

What’s Pfizer’s Financial Guidance for 2017?

2017-04-04 09:06:28

Is Sanofi Pasteur Living Up to Its Name?

2017-04-03 10:39:27

What Have Clinical Trials of Novartis’s LEE011 Demonstrated?

2017-04-03 10:37:59

Recent Developments at Eli Lilly

2017-04-03 09:07:31

The Latest from Sanofi’s Diabetes and Cardiovascular Franchise

2017-04-03 07:36:41

Novartis Is Focused on Creating Shareholder Value in 2017

2017-03-31 09:06:21

How Eli Lilly’s Neuroscience Franchise’s 2016 Turned Out

2017-03-31 07:36:25

Analyzing LLY’s Cardiovascular Franchise’s 2016 Performance

2017-03-30 09:08:07

How Eli Lilly’s Business Segments Performed in 2016

2017-03-30 09:06:31

GlaxoSmithKline’s Consumer Healthcare Segment in 2016

2017-03-29 10:36:40

Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe

2017-03-29 09:30:01

The Zacks Analyst Blog Highlights: HCA Holdings, Molina Healthcare, SPDR S&P Pharmaceuticals ETF, BioShares Biotechnology Products Fund and The Health Care Select Sector SPDR Fund

2017-03-29 09:06:22

Performance of Key Pharmaceuticals Products for GlaxoSmithKline

2017-03-29 07:36:09

What Wall Street Analysts Recommend for Merck

2017-03-28 10:39:16

GlaxoSmithKline’s Segment-Wise Performance in 2016

2017-03-28 07:36:36

How 2016 Treated Alcon, Novartis’s Eyecare Business

2017-03-27 18:04:00

ETF Flyer: Healthcare Stocks Continue To Dance On the Grave Of The Failed GOP Bill

2017-03-24 10:35:43

Bausch & Lomb Continues to be Key Growth Driver for Valeant

2017-03-24 09:05:43

Valeant’s Diversified Products Revenue May Drop in 2017

2017-03-23 09:06:03

New Product Launches May Boost Valeant’s Dermatology Revenue

2017-03-22 10:36:52

Relistor May Be Solid Growth Opportunity for Valeant in 2017

2017-03-22 09:07:54

How AstraZeneca Controlled Operating Expenses in 2016

2017-03-22 07:37:02

Headwinds Seen by Valeant Pharmaceuticals in 2016

2017-03-21 07:37:28

Analysts’ Recommendations for Valeant Pharmaceuticals in 2017

2017-03-20 15:44:42

Billionaire Investor, Millionaire Mistakes

2017-03-20 15:44:42

Billionaire Investor, Millionaire Mistakes

2017-03-20 15:44:42

Billionaire Investor, Millionaire Mistakes

2017-03-20 10:22:02

Trump, Biogen and Amgen Hammer Healthcare ETFs

2017-03-20 10:22:02

Trump, Biogen and Amgen Hammer Healthcare ETFs

2017-03-17 10:37:05

What Cardiovascular Drug Eliquis’s 2016 Looked Like

2017-03-16 15:05:43

Analyzing Bristol-Myers Squibb’s 2016 Performance

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 15:48:00

[$$] Drug Stocks Look Ready To Move Higher

2017-03-15 09:05:56

Johnson & Johnson’s Financial Guidance for 2017

2017-03-15 07:36:28

Johnson & Johnson’s Major Developments

2017-03-14 16:03:05

Aurinia’s stock plunges after big share offering at deep discount

2017-03-13 10:37:11

Johnson & Johnson’s Business Segment Performance

2017-03-10 14:17:49

Trump administration expected to name VC partner Gottlieb to head FDA

2017-03-08 16:20:57

Why Health Care Is The Top Sector Of 2017

2017-03-08 11:06:00

The Bears Take Aim at Pharmaceuticals PPH, PJP

2017-03-08 10:07:03

Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

2017-03-08 10:07:03

Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

2017-03-08 07:07:00

Demand offers big opportunity in health care stocks: Pro

2017-03-08 05:13:38

Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors

2017-03-07 16:05:00

Stocks Fall for Day Two as Trump Targets Health Care Sector

2017-03-07 15:21:27

Analysts Scratch Their Heads Over Trump Drug Price Tweet

2017-03-07 11:34:00

Trump Tweets And Drug Stocks Fall

2017-03-07 09:58:02

Healthcare ETFs in Focus on Obamacare Replacement Plan

2017-03-07 09:58:02

Healthcare ETFs in Focus on Obamacare Replacement Plan

2017-03-07 09:48:55

Trump's Latest Drug Pricing Tweet Hits Biotech Stocks

2017-03-07 09:42:31

Trump's Latest Drug Pricing Tweet Hits Biotech Stocks

2017-03-07 09:16:24

Pharma and biotech stocks slump after President Trump tweets about lowering drug prices

2017-03-06 10:36:21

How Mylan Is Valued after 4Q16 Earnings

2017-03-06 09:06:47

How These Recent Developments Could Affect Mylan

2017-03-06 07:36:36

How Did Mylan’s Rest of the World Segment Perform?

2017-03-03 15:35:43

How Mylan’s Europe Segment Performed

2017-03-01 16:14:09

Best & Worst ETFs of February 2017

2017-03-01 13:24:04

Investors have stopped believing Trump’s drug price threats

2017-03-01 09:06:47

Emerging Markets Expected to Be AstraZeneca’s Key Growth Driver

2017-03-01 08:59:01

Hit ETFs & Stocks from the Top Sector of February

2017-03-01 08:23:31

Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S.

2017-02-28 18:07:07

Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S.

2017-02-28 18:07:07

Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S.

2017-02-28 16:41:44

President Trump’s drug price threats have stopped working since he met with industry

2017-02-28 09:06:03

Eli Lilly & Co.’s Recent Developments

2017-02-28 07:36:47

Pfizer’s Profitability and Financial Guidance

2017-02-27 14:35:43

AstraZeneca’s 4Q16 Revenues Fell 12%

2017-02-27 10:38:09

Pfizer’s Products with Falling Revenues in 4Q16

2017-02-27 08:22:30

Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA

2017-02-27 07:36:57

Eli Lilly & Co.’s Neuroscience Franchise

2017-02-27 07:32:29

La Jolla Pharmaceutical's stock rockets in active trade after positive trial results

2017-02-24 10:38:08

Eli Lilly & Co.’s Cardiovascular Franchise

2017-02-24 10:36:07

Wall Street Analysts’ Estimates for Merck & Co.

2017-02-24 07:39:01

Performance of Eli Lilly & Co.’s Business Segments in 4Q16

2017-02-23 13:50:57

What Analysts Recommend for Teva Pharmaceutical in 2017

2017-02-23 10:37:45

Remicade: Driving Down Merck & Co.’s Immunology Franchise

2017-02-23 07:47:12

Gardasil Driving Merck & Co.’s Vaccines Business in 4Q16

2017-02-22 10:37:08

Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug

2017-02-22 09:08:26

Merck & Co.’s Segment-Wise Revenues for 4Q16

2017-02-22 07:37:31

Merck and Co. Reports Flat Operational Revenues in 4Q16

2017-02-22 07:37:31

Merck & Co. Reported Flat Operational Revenues in 4Q16

2017-02-20 09:06:55

Sanofi’s Unique Foothold in Diabetes and Cardiovascular

2017-02-15 09:07:06

GlaxoSmithKline’s Global Pharmaceuticals Business in 4Q16

2017-02-09 08:00:00

Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback

2017-02-07 16:42:40

Drug stocks dip after Spicer affirms Trump’s stance on cutting costs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-02 09:07:08

Inside Novartis’s Eye Care Performance in 4Q16

2017-02-01 15:05:43

Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16

2017-02-01 13:19:39

Novartis’s 4Q16 Earnings Meet Analysts’ Estimates

2017-02-01 13:10:00

How to Play Pfizer's Fourth-Quarter Results With ETFs

2017-02-01 10:35:55

Bristol-Myers Squibb’s Valuation Compared to Its Peers

2017-02-01 09:06:20

Changes in Bristol-Myers Squibb’s 4Q16 Profitability

2017-02-01 07:36:29

How Other Bristol-Myers Squibb Segments Are Doing

2017-01-31 10:36:51

Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug

2017-01-30 13:35:57

Bristol-Myers Squibb Continued Growth in 4Q16

2017-01-30 11:45:20

Bristol-Myers Squibb: 4Q16 Earnings Show Growth

2017-01-30 10:35:59

What Are Analysts’ Future Estimates for Johnson & Johnson?

2017-01-30 07:36:42

Johnson & Johnson’s 4Q16 Earnings: Major Developments

2017-01-26 12:00:11

Johnson & Johnson Reports Growth in 4Q16

2017-01-26 09:06:33

What to Expect from Eli Lilly’s Cardiovascular Franchise in 4Q16

2017-01-25 12:05:53

Why Eli Lilly Expects to See Revenue Growth in 4Q16

2017-01-24 07:38:33

Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!

2017-01-24 07:36:28

Novartis’s 4Q16 Estimates: Expectations from Alcon

2017-01-23 10:36:07

What’s New with Johnson & Johnson?

2017-01-20 17:41:30

Novartis’s 4Q16 Earnings: What Is Expected?

2017-01-20 09:59:00

A.M. Funds Roundup: Investors Buy Volatility ETFs, Exit Equity ETFs Ahead Of Inauguration,

2017-01-20 09:07:29

How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 08:00:00

Trending: Pound Gains as Theresa May Lays out Brexit Plan

2017-01-17 11:16:00

Biotech ETFs: When Will The Pain End?

2017-01-17 11:16:00

Biotech ETFs: When Will The Pain End?

2017-01-17 10:36:12

How Did Novartis’s Eye Care Business Perform?

2017-01-16 10:37:03

How Is Novartis’s Revenue Trending?

2017-01-13 09:06:51

Mylan’s Recent Commercial and Product Developments

2017-01-13 07:36:31

Mylan’s Profit Margins: What Made Them Change?

2017-01-12 12:01:00

Biotech ETFs Continue To Bleed

2017-01-12 12:01:00

Biotech ETFs Continue To Bleed

2017-01-12 12:00:05

Trump's First Press Conference Puts These ETFs in Focus

2017-01-12 10:37:10

Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales

2017-01-12 10:08:03

Trump Attacks Biotech & Pharma: ETFs Bleed

2017-01-12 07:37:39

Understanding Mylan’s Revenues

2017-01-11 17:05:47

Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

2017-01-11 16:30:00

The Biggest Loser: Endo International Tumbles 8.6%

2017-01-11 13:03:00

2 Stocks For a Trump-ed Up Pharma Market

2017-01-11 12:09:00

Biotech, Pharma ETFs Sink; Trump Promises _Bidding Procedures_

2017-01-11 12:09:00

Biotech, Pharma ETFs Sink; Trump Promises _Bidding Procedures_

2017-01-03 07:36:28

Harvoni: Gilead Sciences’ Blockbuster HCV Drug

2017-01-02 07:36:21

Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business

2016-12-30 10:20:46

AstraZeneca Could See Modest Fall in 2016 Revenues

2016-12-28 10:36:35

VRX’s US Diversified Products Segment Could See Falling Revenues in 2017

2016-12-28 07:36:18

VRX’s Branded Rx Segment Witnessed Drop in Revenues in 2016

2016-12-28 06:52:00

Biotech plays for the new year

2016-12-28 06:49:00

2017 Playbook: Biotech & pharma

2016-12-27 16:24:05

Valeant Pharmaceuticals Could See Modest Revenue Decline in 2016

2016-12-21 11:21:00

Top 5 Pharmaceutical ETFs for 2016

2016-12-21 11:21:00

Top 5 Pharmaceutical ETFs for 2016

2016-12-20 09:06:25

Horizon Pharma’s Orphan Drug Segment: 3Q16 Performance

2016-12-20 08:19:50

Tesaro NDA for ovarian cancer treatment granted priority review

2016-12-20 07:36:30

It Was a Successful 3Q16 for Horizon Pharma’s Primary Care

2016-12-16 08:37:49

Mylan's first generic EpiPen launches at less than half the cost of branded version

2016-12-15 08:05:32

What Do Analysts Recommend for Pfizer?

2016-12-14 08:05:41

Loss of Patent Protection to Drag Pfizer’s Top Line

2016-12-14 06:33:00

How to play health care stocks under Trump: Pro

2016-12-14 06:30:00

Can Trump keep promise to reduce drug prices?

2016-12-13 09:36:01

Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space

2016-12-13 08:06:09

Avelumab: The First US Treatment for Metastatic Skin Cancer?

2016-12-12 11:06:08

How Could Pfizer Drive Growth for Ibrance?

2016-12-12 11:05:50

Johnson & Johnson’s Consumer Segment in 3Q16

2016-12-12 09:36:34

Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

2016-12-12 08:06:15

How Did Pfizer’s Innovative Health Business Perform in 3Q16?

2016-12-09 11:06:06

Johnson & Johnson’s Business Segment Performance in 3Q16

2016-12-08 17:42:50

Express Scripts’ stock rocked by tweets from short seller Andrew Left

2016-12-08 15:00:08

Biotech & Pharma ETFs to Suffer in 2017 Too?

2016-12-08 13:43:38

Express Scripts' stock dives after short seller Andrew Left takes aim

2016-12-07 12:40:08

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

2016-12-07 11:31:00

Biotech ETFs: So Much For The Trump Bounce

2016-12-07 11:31:00

Biotech ETFs: So Much For The Trump Bounce

2016-12-07 09:44:00

Pisani: Trump rally is evolving

2016-12-07 09:29:24

President-elect Trump’s promise to bring down drug prices sends biotech ETFs slumping

2016-12-07 09:29:24

President-elect Trump’s promise to bring down drug prices sends biotech ETFs slumping

2016-12-05 11:05:22

Inside Merck’s Profitability after 3Q16

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 11:05:03

Merck’s Gardasil and What It Could Mean

2016-12-02 11:04:40

Analysts Are Bullish on Valeant

2016-12-02 10:49:03

5 Secret Santa ETFs & Stocks for Your Portfolio

2016-12-01 11:04:50

What’s Forcing Valeant to Sell Its Core Assets?

2016-12-01 10:05:47

Understanding Merck’s Most Recent Product Developments

2016-12-01 08:05:35

How Baxter Continues to Contribute to Patient Care

2016-11-30 18:21:06

A Closer Look at Merck’s Valuation Compared to Peers

2016-11-30 15:04:05

When Will Valeant Resume Its Top Line Growth?

2016-11-30 11:04:30

Has Valeant Really Bottomed Out?

2016-11-30 08:11:32

Five ways to evaluate an Obamacare replacement plan

2016-11-30 08:05:42

What to expect from Tom Price, President-elect Trump’s pick for HHS secretary

2016-11-30 08:05:14

Steady Rise: Allergan’s International Segment in 3Q16

2016-11-29 11:04:28

How Did Gilead Sciences’s HCV Business Perform across Geographies?

2016-11-29 10:05:42

Pfizer Divests Hospira’s Infusion System Business to ICU Medical

2016-11-29 10:04:14

How Was Bristol-Myers Squibb’s Profitability in 3Q16?

2016-11-29 08:04:24

How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

2016-11-28 11:06:15

Gilead Sciences Holds a Broader HIV Portfolio

2016-11-27 16:54:53

Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy?

2016-11-25 12:04:08

Bristol-Myers Squibb Continues Revenue Growth in 3Q16

2016-11-25 09:40:33

How Does Bristol-Myers Squibb’s Valuation Compare to Peers?

2016-11-25 08:04:12

Key Investor Insights into Eli Lilly’s Recent Developments

2016-11-24 11:04:34

Patent Litigations to Delay Teva’s New Product Launches

2016-11-23 10:04:42

What You Need to Know about Eli Lilly’s Cardiovascular Franchise

2016-11-23 08:04:57

Beyond Oncology: BMY’s Eliquis, a Key Growth Driver

2016-11-23 08:04:44

What You Need to Know about Eli Lilly’s Endocrine Franchise

2016-11-22 17:00:00

VanEck Announces Preliminary Year-End Distribution Estimates for VanEck Vectors Equity ETFs

2016-11-22 15:04:05

Understanding Eli Lilly’s Business Segments by 3Q16 Performance

2016-11-22 11:04:18

What Do the Analysts Recommend for Bristol-Myers Squibb’s Stock?

2016-11-22 10:04:21

Inside Bristol’s Key to Success: Multiple Labels for Opdivo

2016-11-22 08:05:01

SD-809 Could Be a Strong Growth Driver for Teva Pharmaceutical

2016-11-21 13:35:57

Teva Pharmaceutical Expected to Report Robust Revenue in 2016

2016-11-18 17:04:10

Understanding Bristol’s Blockbuster: Opdivo’s Edge over Keytruda

2016-11-18 08:04:22

Novartis’s Alcon Continues Its Falling Trend in 3Q16

2016-11-17 12:18:00

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

2016-11-17 12:18:00

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

2016-11-17 08:04:58

Novartis’s Revenue Trend in 3Q16

2016-11-16 17:04:08

Novartis’s 3Q16 Earnings Surpass Analyst Estimates

2016-11-16 13:51:45

Most Analysts Rate Novartis a ‘Buy’

2016-11-15 16:15:03

Biotech takes Trump presidency as a green light — and end to drug price worries

2016-11-15 11:04:15

An Update on Valeant’s R&D Program

2016-11-15 10:04:11

Why Did Valeant Revise Its 2016 EPS Guidance?

2016-11-14 11:04:28

Why AstraZeneca’s Respiratory Segment Is a Key Growth Platform

2016-11-14 10:57:03

5 Reasons to Buy 5 Low P/E Biotech ETFs

2016-11-14 10:04:30

Branded Rx Still a Pain for Valeant Pharmaceuticals

2016-11-14 08:04:50

The Performance of AstraZeneca’s Growth Platforms in 3Q16

2016-11-14 08:04:30

How Did the Bausch & Lomb Division Perform in 3Q16?

2016-11-14 07:52:56

Corbus Pharmaceuticals stock more than doubles after positive drug trial results

2016-11-11 15:52:25

AstraZeneca’s Valuation and 3Q16 Earnings

2016-11-11 10:05:01

Valeant Pharmaceuticals Fell on Lowered Growth Outlook

2016-11-11 08:04:54

Great Disappointment in Valeant Pharmaceuticals’s 3Q16 Earnings

2016-11-10 11:26:32

The death of Obamacare will bring new opportunities for investors

2016-11-10 06:25:20

Valeant’s 3Q16 Earnings: What Will Drive Its Revenue?

2016-11-09 10:08:00

Trump Victory Big For Biotech

2016-11-08 16:31:45

Generic-drug maker ETF could outperform biotech peers under Clinton

2016-11-08 10:04:29

Pfizer’s 3Q16 Earnings: Profitability and Financial Guidance

2016-11-07 14:04:13

Why Valeant Has Been in the News Recently

2016-11-07 11:53:59

What Do Analysts Recommend for Valeant after Recent Happenings

2016-11-07 11:42:18

Mr. Wonderful's Election Week Trades For A Trump Victory

2016-11-07 10:02:03

Healthcare ETFs in the Spotlight as Election Approaches

2016-11-07 10:02:03

Healthcare ETFs in the Spotlight as Election Approaches

2016-11-04 13:15:00

Healthcare: _A Better Buy Than A Sell_

2016-11-04 08:04:11

What Do Analysts Recommend for Novo?

2016-11-03 13:03:31

Valeant’s Salix Acquisition Saga

2016-11-02 08:06:30

How Much Did Novo Get from International Regions in 3Q16?

2016-11-01 15:42:35

Eli Lilly's Stock Prices Feels the Bern

2016-11-01 14:57:25

Honing in on Novo’s 3Q16 Revenue and Earnings

2016-11-01 10:04:42

What Will Be Pfizer’s Profitability in 3Q16?

2016-11-01 08:04:47

Behind the Recent Developments in Pfizer’s 3Q16 Estimates

2016-10-31 17:39:23

Can Key Level Stop The Bleeding In Health Care Stocks?

2016-10-31 11:04:33

Remicade: Driving Down Merck’s Immunology Franchise

2016-10-31 10:05:17

Understanding the Growth Contributors in Pfizer’s 3Q16 Estimates

2016-10-31 10:04:36

Januvia and Janumet: Merck’s Blockbuster Diabetes Products

2016-10-31 08:06:08

Can Pfizer Recover Growth in 3Q16 Earnings?

2016-10-28 15:04:08

Keytruda: The New Blockbuster of Merck’s Immuno-Oncology Franchise

2016-10-28 12:07:00

3 ETFs to Buy If You Think Pfizer Will Beat Earnings

2016-10-26 11:04:27

Expectations from Other Segments for Bristol-Myers Squibb in 3Q15

2016-10-25 11:45:42

Bristol-Myers Squibb’s 3Q16 Earnings: What’s Expected

2016-10-25 10:04:05

Analyzing Future Estimates for Johnson & Johnson

2016-10-24 11:04:11

Major Developments for Johnson & Johnson in 3Q16

2016-10-21 18:04:10

Do Analysts Expect Negative Growth for Novartis in 3Q16?

2016-10-21 11:04:08

Earnings ahead! What Analysts Expect for Eli Lilly and Co.

2016-10-21 10:05:38

A Look at Johnson & Johnson’s Segment-Wise Performance in 3Q16

2016-10-20 17:48:11

Another Health Care Chart Looks Sick

2016-10-20 17:48:11

Another Health Care Chart Looks Sick

2016-10-20 08:04:42

Eli Lilly and Co.’s 3Q16 Estimates: Cardiovascular Franchise

2016-10-19 08:06:45

Eli Lilly’s 3Q16 Estimates: Expect Revenue Growth!

2016-10-18 10:05:32

How Valeant Is Expected to Pay down Its Debt

2016-10-17 17:04:26

Valeant Counts on Baush + Lomb for Revenue Growth

2016-10-17 13:17:24

Valeant Looks to Line Its Coffers Using These Five Strategies

2016-10-17 08:04:25

This Space Presents a Market Opportunity for Valeant

2016-10-15 10:01:00

How To Invest If Hillary Clinton Wins The Election

2016-10-14 11:04:38

How Much Is Pfizer’s Return Potential?

2016-10-14 10:04:39

Valeant Looks to Boost Profit Margins through the Walgreens Deal

2016-10-14 10:04:37

Pfizer’s Divestment of Hospira Infusion Systems

2016-10-13 17:04:05

Valeant Thinks It Will Hit Its Financial Targets in 2016

2016-10-13 14:04:14

What Are Pfizer’s Major Growth Concerns?

2016-10-13 13:53:04

Valuation Multiples: How Valeant Compares to Its Peers

2016-10-12 10:04:25

BMY’s Drug Treatments That Go beyond Immuno-Oncology

2016-10-11 11:04:56

BMY Waiting to Enter the First-Line Lung Cancer Space

2016-10-11 08:04:43

What Do Analysts Have to Say about Bristol-Myers Squibb?

2016-10-10 11:04:46

Keytruda Leads over Opdivo in Head and Neck Cancer Treatment

2016-10-07 13:16:05

Is the Dividend ETF Bull Run Over?

2016-10-05 09:42:00

3 ETFs to Buy for a Media Merger Frenzy

2016-10-04 10:04:59

A Look at Gardasil and Merck & Co.’s Vaccines Business

2016-10-03 10:05:21

Why Generic Drugs Will Play a Key Role in the Future

2016-10-03 10:05:21

Why Generic Drugs Will Play a Key Role in the Future

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-09-30 19:04:27

Understanding Merck’s Business Segments and Their Revenue Trends

2016-09-30 17:35:00

Announcing VanEck Vectors Equity ETFs’ September 2016 Distributions

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:05:21

Which Pfizer Products Reported Declining Sales?

2016-09-30 10:05:19

Novo Nordisk Continues to Be a Leader in the Global Insulin Market

2016-09-29 18:04:12

The Pfizer-Anacor Deal: A Review

2016-09-29 10:04:45

Teva Expects Significant Value Addition from Growth Markets

2016-09-28 10:04:16

Is Teva Positioned to Compete with the Likes of Mylan and Novartis?

2016-09-27 18:10:31

Teva Is Well Positioned for New Trends in the US Generic Market

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-26 11:05:05

How Mylan’s Profitability Has Changed

2016-09-26 10:05:41

And Then There’s Mylan’s Specialty Segment, Home of the EpiPen

2016-09-26 08:06:21

What’s Driving Growth in Mylan’s Generics Segment?

2016-09-23 19:04:05

Generics or Specialty: Which Mylan Segment Is Growing Fastest?

2016-09-23 17:25:53

Teva’s Valuation Multiples Compared to Other Generic Drug Players

2016-09-23 17:04:10

You’ve Heard about the EpiPen Debacle, but Have You Heard This?

2016-09-23 15:20:52

Are Mylan’s EpiPen Challenges Souring Analysts’ Views on Stock?

2016-09-22 10:00:00

Trending on ETFdb.com: Politics and Central Banks Move Markets

2016-09-21 11:05:03

How Analysts See Horizon Compared to Its Peers

2016-09-21 10:04:59

How Procysbi Fits into Horizon’s Existing Orphan Drug Portfolio

2016-09-20 12:04:15

News of Acquisition Caused Horizon Pharma Stock to Rise

2016-09-20 11:04:57

Teva, Eli Lilly Have Migraine Treatments in Trial Phases

2016-09-20 08:04:48

Valeant’s Strategies for Its Dermatology, Gastroenterology Drugs

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 16:04:12

How Valeant Plans to Its Fix Dermatology Portfolio

2016-09-19 15:04:09

Projected Revenue for Valeant in 2017

2016-09-19 12:59:52

Understanding Valeant’s Improved Valuation Multiple

2016-09-12 14:47:42

M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound

2016-09-12 10:00:00

VanEck to Ring The Nasdaq Stock Market Opening Bell

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 08:05:10

Pfizer’s Hospira Deal: Catching Up a Year Later

2016-09-08 11:18:14

Understanding Sanofi’s Strategic Priority

2016-09-06 11:22:03

Top Sector ETFs of Summer

2016-09-05 11:04:16

Animal Health: Just as Important to Eli Lilly as Human Health

2016-09-05 11:04:05

Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?

2016-09-05 08:04:05

Why Pfizer’s Enbrel Faces a Sales Decline

2016-09-01 11:04:32

How Are Eli Lilly’s Business Segments Performing?

2016-09-01 11:04:13

Why Pfizer’s Vaccines Business Is Declining

2016-08-31 11:05:02

Will Xtandi Fuel Pfizer’s Top-Line Growth?

2016-08-31 10:58:00

Biotech Leads the Way in Health Care Stocks to Boost 401k Returns

2016-08-31 10:58:00

Biotech Leads the Way in Health Care Stocks to Boost 401k Returns

2016-08-31 10:05:13

Why Pfizer Is Trading at a Discount on an Earnings Basis

2016-08-30 14:04:19

Analyzing Johnson & Johnson’s Business Segments

2016-08-30 10:04:39

Akorn in 2016: What Are Its Key Risk Factors?

2016-08-24 10:04:05

Why Did Hormel Foods Increase Its Fiscal 2016 Guidance?

2016-08-23 09:30:01

The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware ETF, PowerShares Dynamic Semiconductors ETF, SPDR S&P Health Care Services ETF and PowerShares DWA Utilities Momentum ETF

2016-08-11 11:04:54

Pfizer’s Products with Decreasing Revenues

2016-08-04 09:47:23

Top Tech ETFs Of 2016

2016-08-03 12:22:04

Pharma ETFs Soaring on Solid Q2 Earnings

2016-08-03 09:04:13

Gilead Sciences Continues to Focus on Improving Care for HCV Patients

2016-06-04 18:00:00

Why This Healthcare ETF Was Last Week's Biggest Winner

2016-06-02 11:00:00

Trending on ETFdb.com: Emerging Markets and Dividend Kings Garner Interest

2016-05-27 11:37:34

Government Study: Cellphone Radiation Linked To Cancer

2016-05-14 15:52:00

Last Week's Best Healthcare ETF

2016-05-07 10:01:08

Mudslinging Over Valeant Pharmaceuticals

2016-05-04 14:50:06

Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus

2016-05-04 09:00:08

Finding Pharmaceuticals ETFs With Rebound Potential

Comments

You have to sign in to write a comment.

No comments yet.